-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $416

Benzinga·07/07/2026 12:20:08
Listen to the news
Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $413 to $416.